PREDICTIMMUNE
PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing Inflammatory Bowel Disease (both Crohn’s and ulcerative colitis). Based on world-leading research at Cambridge University, UK, they are developing a simple lab test, using a small blood sample, which accurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease. These patients are likely to benefit from early biologics therapy. Physicians, patients and payors all recognise the value of such an approach to the management of Inflammatory Bowel Disease.
PREDICTIMMUNE
Industry:
Biopharma Biotechnology Health Care Life Science Medical Medical Device
Founded:
2017-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.predictimmune.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0)1223 804 195
Total Funding:
31.44 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network LetsEncrypt
Similar Organizations
Healx
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Metabolomic Diagnostics
Metabolomic Diagnostics specializes in the development of novel biomarker based diagnostic solutions for complex diseases
Pilot Biotechnology
Pilot Biotechnology is an industrial biotechnology company engaged in the development, production, and sales of health care products.
TPM
Tpm.bio specializes in research, life sciences services, training on medical devices, and innovation in the biomedical field.
Current Advisors List
Advisor
2017-05-01
Current Employees Featured
Eoin McKinney Chief Scientific Officer & Co-Founder @ PredictImmune
Chief Scientific Officer & Co-Founder
Paul Foulger CFO @ PredictImmune
CFO
2017-05-01
Kenneth Smith Co-Founder & Chief Medical Officer @ PredictImmune
Co-Founder & Chief Medical Officer
Andrew P Sandham Chairman @ PredictImmune
Chairman
Paul Lyons Vice President of Platform Delivery & Co-Founder @ PredictImmune
Vice President of Platform Delivery & Co-Founder
Alastair Kilgour Non Executive Director @ PredictImmune
Non Executive Director
2017-05-01
Founder
Investors List
Crohn's & Colitis Foundation
Crohn's & Colitis Foundation investment in Grant - PredictImmune
Parkwalk Advisors
Parkwalk Advisors investment in Series A - PredictImmune
Parkwalk Advisors
Parkwalk Advisors investment in Series B - PredictImmune
Cambridge Innovation Capital
Cambridge Innovation Capital investment in Series B - PredictImmune
University of Cambridge Enterprise
University of Cambridge Enterprise investment in Series B - PredictImmune
Business Growth Fund
Business Growth Fund investment in Series B - PredictImmune
Innovate UK
Innovate UK investment in Grant - PredictImmune
Wellcome Trust
Wellcome Trust investment in Grant - PredictImmune
Parkwalk Advisors
Parkwalk Advisors investment in Series A - PredictImmune
Wren Capital
Wren Capital investment in Series A - PredictImmune
Official Site Inspections
http://www.predictimmune.com Semrush global rank: 10.15 M Semrush visits lastest month: 253
- Host name: 192.64.119.79
- IP address: 192.64.119.79
- Location: Los Angeles United States
- Latitude: 34.0318
- Longitude: -118.4252
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90064
More informations about "PredictImmune"
Predictimmune and the Crohn’s & Colitis Foundation Announce a …
Dec 4, 2018 CAMBRIDGE, England—PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, …See details»
PredictImmune 2025 Company Profile: Valuation, Funding
PredictImmune General Information Description. Developer of prognostic tools designed to guide treatment options in immune-mediated inflammatory diseases. The company's products offer …See details»
Cambridge spin-out PredictImmune closes Series B, raising £10m
Jul 30, 2019 Cambridge Enterprise portfolio company PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune …See details»
PredictImmune - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Series A - PredictImmune — …See details»
PREDICTIMMUNE LIMITED - Companies House
Company Overview for PREDICTIMMUNE LIMITED (10563794) Filing history for PREDICTIMMUNE LIMITED (10563794) People for PREDICTIMMUNE LIMITED (10563794) …See details»
PredictImmune - Craft
PredictImmune is a developer of prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases. The company aims to develop and …See details»
Spin-out PredictImmune wins £4.3m from Wellcome to …
Apr 30, 2018 PredictImmune, a developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded £4.3m by the Wellcome Trust.. The funding will be used to support a …See details»
New agreement with Cambridge spin-out PredictImmune lets SLE …
Sep 19, 2019 PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed the …See details»
PredictImmune Company Information - Funding, Investors, and …
Get information on funding, investors, industries, and more for PredictImmune. See PredictImmune company profile and funding data.See details»
PredictImmune – Personalised treatment for immune …
PredictImmune is a global biotechnology company applying innovative technology to the development of products to enable precision medicine in immune-mediated inflammatory diseases (IMIDs) such as Crohn’s Disease (CD), Multiple …See details»
PredictImmune secures $5.9M in funding for its Crohn’s disease ...
Apr 30, 2018 PredictImmune, a U.K.-based developer of diagnostics, secured $5.9 million (£4.3 million) in funding from the Wellcome Trust that will be used for a multisite clinical trial of its …See details»
PredictImmune: Predicting outcomes in Inflammatory Bowel …
PredictImmune is the manufacturer and distributer of PredictSURE IBD, a CE marked assay (since 2018) which has been available for commercial use through the East Genomic …See details»
PredictImmune to Expand Pipeline with SLE Prognostic Tool
Sep 30, 2019 The new deal grants PredictImmune “first right of refusal” to technology that will allow the development and commercialization of a prognostic test to help monitor SLE …See details»
PredictImmune Raises €11M to Market Personalized Medicine Test
Jul 31, 2019 The UK biotech PredictImmune has raised €11M (£10M) in a Series B fundraising round to commercialize technology to predict the progress of inflammatory bowel disease in …See details»
PredictImmune announces new strategic partnership
Oct 22, 2019 PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed that it has entered into an exclusive commercial partnership with KSL Biomedical (KSL), to commercialise and provide PredictImmune’s prognostic test for inflammatory bowel disease …See details»
PredictImmune Partners with Foundation on Study to Validate IBD …
Nov 7, 2019 PredictImmune successfully launched the test in the U.K. and Ireland in April, and since then has worked to expand the test’s distribution worldwide. On October 22, …See details»
PredictImmune - IBD Relief
About PredictSURE IBD™ Award-winning PredictSURE IBD™, made by PredictImmune, is the world’s first validated and CE-marked prognostic test for guiding treatment options in …See details»
PredictImmune announces commencement of PRECIOUS study
Nov 8, 2019 “The study takes both PredictImmune and the Crohn’s & Colitis Foundation a step closer to a common goal of improving disease outcomes and quality of life for patients with …See details»
New prognostic test could enable personalised treatment of …
May 3, 2019 The test is now being developed further by PredictImmune, a spinout company co-founded by Professor Smith with support from Cambridge Enterprise, the University’s …See details»
PredictImmune’s first prognostic test for IBD, PredictSURE IBD ...
Cambridge, UK, 2nd April: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today …See details»